Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study BioSpaceA single 1-mg/kg dose of Eli Lilly's base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) BioSpace A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRCNext: Arthrosi drug trial in gout delivers for new owner Sobi Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
